Katsuyuki Kiura - Concepedia

Author

Katsuyuki Kiura

Also Known As

F. Nomura, Junichi Soh, K Kiura, K. Katsuyuki, K. Kiura, KATSUYUKI KIURA, KATSUYUKI KIURA, M.D., Kastuyuki Kiura, Katsuyuki KIURA, Katsuyuki Kiura

Publications

17.5K

Citations

H-Index

184

Concepts

All Affiliations

Okayama University Okayama University Hospital Shikoku Cancer Center Kawasaki Medical School Okayama Medical Center

About

Katsuyuki Kiura is an author at Okayama University specializing in medicine, lung cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	45	186	8K
2	Health Sciences	20	39	1.6K
3	Engineering	2	2	328
4	Public Health	2	2	33
5	Language Studies	1	1	16

Katsuyuki Kiura

308

Publications

14.6K

Citations

H-Index

Page 1

	Year	Citations
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study Takashi Seto, Katsuyuki Kiura, Makoto Nishio, The Lancet Oncology Non-small-cell Lung CancerMedicinePathologyAf-001jp StudyBronchial Neoplasm	2013	576
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial Alice T. Shaw, Tae Min Kim, Lucio Crinò, The Lancet Oncology MedicineCeritinib Versus ChemotherapyPathologyBronchial NeoplasmCancer Treatment	2017	574
The Relationship between Epidermal Growth Factor Receptor Mutations and Clinicopathologic Features in Non–Small Cell Lung Cancers Masaki Tokumo, Shinichi Toyooka, Katsuyuki Kiura, Clinical Cancer Research	2005	495
Presence of<i>Epidermal Growth Factor Receptor</i>Gene T790M Mutation as a Minor Clone in Non–Small Cell Lung Cancer Michio Inukai, Shinichi Toyooka, Sachio Ito, Cancer Research	2006	444
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor <i>BRAF</i> gene mutations but lack mutations in <i>KRAS, NRAS,</i> or <i>MEK1</i> Kadoaki Ohashi, Lecia V. Sequist, Maria E. Arcila, Proceedings of the National Academy of Sciences	2012	434
LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both Nobuyuki Katakami, Shinji Atagi, Kōichi Goto, Journal of Clinical Oncology	2013	323
Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cell–like Properties in Cancer Cells Kazuhiko Shien, Shinichi Toyooka, Hiromasa Yamamoto, Cancer Research PathologyStem Cell BiologyCancer BiologyTumor BiologyCancer Cell Biology	2013	270
Phase III Trial Comparing Docetaxel and Cisplatin Combination Chemotherapy With Mitomycin, Vindesine, and Cisplatin Combination Chemotherapy With Concurrent Thoracic Radiotherapy in Locally Advanced Non–Small-Cell Lung Cancer: OLCSG 0007 Yoshihiko Segawa, Katsuyuki Kiura, Nagio Takigawa, Journal of Clinical Oncology	2010	246
Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort Seiji Yano, Tadaaki Yamada, Shinji Takeuchi, Journal of Thoracic Oncology Acquired ResistanceMedicineKinase InhibitorsPathologyBronchial Neoplasm	2011	217
Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer Seiji Niho, Hideo Kunitoh, Hiroshi Nokihara, Lung Cancer	2012	211

Page 1